Heidelberg Pharma AG

Regulatory Filings • Aug 4, 2009

News Details

Ad-hoc | 4 August 2009 16:22

WILEX AG: WILEX has filed application for approval of Phase I trial for WX-554 and thereby achieves first milestone of the strategic alliance with UCB

WILEX AG / Regulatory Admission

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Munich, 04 August 2009. The Munich-based biopharmaceutical company WILEX AG
(ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced
that it has filed an application with the German Federal Institute for
Drugs and Medical Devices (BfArM) for the approval of a Phase I trial with
the MEK inhibitor WX-554 and today received the confirmation of receipt.
The orally available, small-molecule MEK inhibitor is one of five oncology
preclinical programmes obtained under the strategic alliance agreed with
UCB Pharma S.A., Brussels, Belgium, in January 2009. The application for
approval to conduct a clinical trial marks the achievement of the milestone
for which WILEX is now eligible for an agreed payment of EUR 5 million.

Contact
WILEX AG
Katja Arnold (CIRO)
Investor & Public Relations
Grillparzerstr. 10
81675 Munich
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors@wilex.com

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
04.08.2009 Financial News transmitted by DGAP

---

Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---